GlaxoSmithKline Pakistan Limited

KASE:GLAXO Stock Report

Market Cap: PK₨44.0b

GlaxoSmithKline Pakistan Past Earnings Performance

Past criteria checks 1/6

GlaxoSmithKline Pakistan's earnings have been declining at an average annual rate of -12.4%, while the Pharmaceuticals industry saw earnings growing at 6.3% annually. Revenues have been growing at an average rate of 8.5% per year. GlaxoSmithKline Pakistan's return on equity is 3%, and it has net margins of 1.2%.

Key information

-12.4%

Earnings growth rate

-12.4%

EPS growth rate

Pharmaceuticals Industry Growth20.2%
Revenue growth rate8.5%
Return on equity3.0%
Net Margin1.2%
Next Earnings Update30 Jul 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How GlaxoSmithKline Pakistan makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KASE:GLAXO Revenue, expenses and earnings (PKR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2453,8786696,6720
31 Dec 2349,6615346,5280
30 Sep 2348,7771,2916,2810
30 Jun 2346,9331,5106,0680
31 Mar 2344,6151,9685,5510
31 Dec 2241,8422,4635,1390
30 Sep 2240,1783,2334,4820
30 Jun 2238,0784,2804,0140
31 Mar 2237,5935,5543,8750
31 Dec 2136,6615,3543,8570
30 Sep 2135,0823,9074,0630
30 Jun 2136,0693,8383,9500
31 Mar 2134,7503,6753,8180
31 Dec 2035,0903,3754,0640
30 Sep 2037,3423,6124,2190
30 Jun 2034,7013,4104,2550
31 Mar 2036,2482,9344,1920
31 Dec 1936,5823,0414,3080
30 Sep 1934,5583,1854,3510
30 Jun 1934,4362,8024,4520
31 Mar 1933,2522,8504,7560
31 Dec 1834,0073,2324,4590
30 Sep 1834,1652,6214,5380
30 Jun 1833,7902,8684,4010
31 Mar 1833,5073,1144,2800
31 Dec 1732,7743,0274,1300
30 Sep 1731,5973,2653,8360
30 Jun 1730,8553,1743,7560
31 Mar 1729,8402,9003,7210
31 Dec 1627,5642,6453,6410
30 Sep 1626,1712,1733,3430
30 Jun 1625,0622,7163,3490
31 Mar 1624,2012,6083,5730
31 Dec 1523,8222,5113,4780
30 Sep 1523,3222,4213,7080
30 Jun 1523,2381,5343,7560
31 Mar 1522,5801,5653,3620
31 Dec 1422,8431,5353,4580
30 Sep 1423,6511,2913,6970
30 Jun 1423,9441,0793,8030
31 Mar 1424,8751,1034,3010
31 Dec 1325,2311,0624,4770
30 Sep 1324,9321,2474,4910

Quality Earnings: GLAXO has high quality earnings.

Growing Profit Margin: GLAXO's current net profit margins (1.2%) are lower than last year (4.4%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: GLAXO's earnings have declined by 12.4% per year over the past 5 years.

Accelerating Growth: GLAXO's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: GLAXO had negative earnings growth (-66%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (22%).


Return on Equity

High ROE: GLAXO's Return on Equity (3%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.